Across 352 CTIS-authorized orphan drug Phase III trials in Europe, 298 listed at least one CRO or outsourced provider, equal to 84.7% of the cohort. IQVIA, PPD / Thermo Fisher, and ICON were the most frequent full-service CRO groups, while CRO use rose most clearly with geographic complexity: 146 of 156 trials spanning 7 or more countries used CRO support.
Among the 298 CRO-supported orphan drug Phase III trials, IQVIA appeared in 93 trials, PPD / Thermo Fisher in 89, ICON in 78, Parexel in 57, and Syneos Health in 42. The leading groups are therefore concentrated among large global CROs with capacity to support CTIS submissions, multi-country operations, central services, and site activation across Europe.
The market is broad but top-heavy. IQVIA, PPD / Thermo Fisher, and ICON together appear as the clearest leaders, while Parexel, Syneos Health, Labcorp, Fortrea, and Medpace form the next tier of recurring orphan Phase III CRO support.
CRO use increased most clearly with country footprint: 18 of 35 single-country trials used CRO support, compared with 146 of 156 trials spanning 7 or more countries. Site footprint also showed high CRO reliance, with 109 of 124 trials using CROs once the trial included 31 or more sites.
CRO need appears to rise most sharply when the trial becomes a multi-country CTIS execution problem. The operational threshold is not only patient volume; the main signal is the combination of EU regulatory coordination, country start-up, site activation, monitoring, and local execution.
Multiple myeloma was the largest CRO-supported disease group, with 24 of 29 trials using CRO or outsourced-provider support. Several operationally complex rare disease groups had universal or near-universal CRO use, including generalized myasthenia gravis, spinal muscular atrophy, paroxysmal nocturnal hemoglobinuria, and ATTR amyloidosis / ATTR-CM.
| Disease group | CRO-supported | Use rate | Sites |
|---|---|---|---|
| Multiple myeloma | 24 / 29 | 82.8% | 1,541 |
| Generalized myasthenia gravis | 10 / 10 | 100.0% | 196 |
| B-cell lymphoma / DLBCL | 9 / 10 | 90.0% | 567 |
| ATTR amyloidosis / ATTR-CM | 9 / 10 | 90.0% | 509 |
| Acute myeloid leukemia | 8 / 10 | 80.0% | 315 |
| Follicular lymphoma | 7 / 10 | 70.0% | 346 |
| Spinal muscular atrophy | 7 / 7 | 100.0% | 99 |
| Paroxysmal nocturnal hemoglobinuria | 7 / 7 | 100.0% | 91 |
CRO opportunity is strongest where orphan indications still require broad European site networks. Multiple myeloma, lymphoma, ATTR amyloidosis, acute leukemia, neuromuscular disease, and complement-mediated disorders show repeated need for coordinated country, site, endpoint, and patient-flow operations.
The most frequently outsourced function categories were central lab or biomarker testing in 286 of 352 trials, eClinical systems in 264, imaging or endpoint review in 230, clinical monitoring or trial management in 227, and regulatory / CTIS submission support in 207.
Outsourcing is not limited to full-service trial management. The highest-frequency outsourced work sits around specialist infrastructure: lab and biomarker workflows, eClinical systems, endpoint review, imaging, monitoring, CTIS submission support, and statistical analysis.
Country-level workload was concentrated in the largest European trial markets. Italy appeared in 253 trials, Spain in 249, France in 246, and Germany in 241. These four countries also carried the largest site and participant workloads, creating the strongest CTIS coordination burden for multi-country orphan Phase III execution.
| Country | Trials | Sites | Participants |
|---|---|---|---|
| Italy | 253 | 1,572 | 8,319 |
| Spain | 249 | 1,434 | 6,017 |
| France | 246 | 1,644 | 7,960 |
| Germany | 241 | 1,258 | 7,268 |
| Poland | 165 | 621 | 3,215 |
| Belgium | 150 | 447 | 1,724 |
| Netherlands | 145 | 419 | 2,675 |
| Czechia | 109 | 307 | 1,884 |
| Austria | 92 | 219 | 1,161 |
| Greece | 85 | 254 | 1,231 |
The CTIS and EU submission workload is most concentrated where large country footprints overlap with large site networks. Italy, Spain, France, and Germany should be viewed as the core operational markets for orphan Phase III trial execution in this cohort.
CRO use was highest among pharma sponsors, with 285 of 310 pharma-sponsored trials using CRO or outsourced-provider support. CRO use was also high in operationally specialized modalities, including 33 of 35 oligonucleotide trials and 20 of 22 gene therapy trials.
CRO use is most consistently associated with sponsor type, cross-border execution, and modality specialization. Pharma-led orphan Phase III trials, US-sponsored trials entering Europe, and advanced therapeutic modalities are especially likely to require outsourced clinical, regulatory, data, and operational support.
CRO means contract research organization. CTIS means Clinical Trials Information System, the European Union portal and database used for clinical trial authorization and supervision under the EU Clinical Trials Regulation. EDC means electronic data capture, eCOA means electronic clinical outcome assessment, IMP means investigational medicinal product, and DLBCL means diffuse large B-cell lymphoma.